Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Compass Therapeutics (CMPX) EBITDA Margin (2024)

Compass Therapeutics (CMPX) has disclosed EBITDA Margin for 1 consecutive years, with 1538.47% as the latest value for Q2 2024.

  • Quarterly EBITDA Margin changed N/A to 1538.47% in Q2 2024 from the year-ago period, while the trailing twelve-month figure was 6463.88% through Mar 2025, changed N/A year-over-year, with the annual reading at 5788.47% for FY2024, N/A changed from the prior year.
  • EBITDA Margin hit 1538.47% in Q2 2024 for Compass Therapeutics.
  • In the past five years, EBITDA Margin ranged from a high of 1538.47% in Q2 2024 to a low of 1538.47% in Q2 2024.